NovoMix: Uses, Dosage & Side Effects
Biphasic insulin aspart (soluble insulin aspart / insulin aspart protamine) — Premixed insulin analogue for diabetes management
Quick Facts About NovoMix
Key Takeaways About NovoMix
- Two insulins in one injection: NovoMix 50 combines rapid-acting and intermediate-acting insulin aspart in a single subcutaneous injection, covering both mealtime glucose spikes and background insulin needs
- Inject immediately before a meal: Because insulin aspart starts working within 10–20 minutes, administer NovoMix immediately before eating, or shortly after the meal if needed
- Hypoglycaemia is the main risk: Low blood glucose (hypoglycaemia) is the most common side effect — always carry a fast-acting sugar source such as glucose tablets or juice
- Never share pens: Insulin pens must never be shared between patients, even if the needle is changed, due to the risk of transmitting blood-borne infections
- Storage matters: Unopened FlexPens are stored in the fridge (2–8°C); in-use pens can be kept at room temperature (below 30°C) for up to 4 weeks and must not be refrigerated again
What Is NovoMix and What Is It Used For?
NovoMix 50 is a biphasic insulin analogue used to treat diabetes mellitus. It contains 50% soluble rapid-acting insulin aspart and 50% protamine-crystallised intermediate-acting insulin aspart, delivering both mealtime and basal insulin coverage from a single subcutaneous injection.
NovoMix 50 belongs to a class of medications known as biphasic insulin analogues. Insulin aspart is a genetically engineered form of human insulin in which the amino acid proline at position B28 is substituted with aspartic acid. This single structural change reduces the tendency of insulin molecules to form hexamers at the injection site, allowing faster absorption into the bloodstream and a quicker onset of action than regular soluble human insulin.
The "biphasic" name reflects the two distinct kinetic phases of the product. The soluble component (50% insulin aspart) starts lowering blood glucose within 10–20 minutes of injection and peaks within 1–4 hours, mimicking the natural insulin release that occurs with meals. The protamine-crystallised component (50% insulin aspart protamine) is absorbed more slowly from the subcutaneous depot, extending the overall duration of action to approximately 14–24 hours and providing a background (basal) insulin effect between meals.
NovoMix is prescribed for patients with type 1 diabetes mellitus, where the pancreas produces little or no insulin due to autoimmune destruction of pancreatic beta cells, and type 2 diabetes mellitus, where the body develops insulin resistance and eventually fails to produce enough insulin to maintain normoglycaemia. It is approved for use in adults, adolescents, and children aged 10 years and older who need insulin therapy to achieve and maintain adequate glycaemic control.
Insulin therapy, including biphasic formulations such as NovoMix, is a cornerstone of diabetes management as recommended by the World Health Organization (WHO), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). Tight glycaemic control with insulin significantly reduces the long-term risk of microvascular complications including diabetic retinopathy, nephropathy, and peripheral neuropathy, as demonstrated in landmark trials such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS).
The NovoMix family includes three different mixtures that differ in the proportion of rapid-acting to intermediate-acting insulin aspart: NovoMix 30 (30% rapid / 70% intermediate), NovoMix 50 (50% rapid / 50% intermediate), and NovoMix 70 (70% rapid / 30% intermediate). The choice between these formulations is made by the prescribing physician based on the patient's individual blood glucose profile, dietary habits, and therapeutic goals. Higher rapid-acting proportions offer stronger control over postprandial glucose excursions, while higher intermediate proportions provide longer background coverage.
In insulin aspart, the amino acid proline at position B28 of the insulin molecule is replaced by aspartic acid. This modification weakens the natural tendency of insulin molecules to cluster into hexamers at the injection site. Because hexamers must first dissociate into monomers before they can be absorbed, insulin aspart is absorbed significantly faster than regular human insulin. Clinically, this means onset of action within approximately 10–20 minutes (vs. 30–60 minutes for regular insulin), a higher peak concentration, and a shorter duration of action — better matching the physiological insulin response to a meal.
What Should You Know Before Taking NovoMix?
Before starting NovoMix, tell your doctor about all medical conditions, other medications, and any previous allergic reactions to insulin or protamine. Never inject NovoMix when your blood sugar is already low (hypoglycaemia), and do not use it if you are allergic to insulin aspart or any of the excipients.
Contraindications
NovoMix must not be used in the following situations:
- Hypoglycaemia: Never inject insulin when blood glucose is already low. Doing so can cause a dangerous further drop that may lead to loss of consciousness, seizures, coma, or death
- Hypersensitivity: Do not use if you have a known allergy to insulin aspart, protamine sulfate, or any of the other ingredients in the formulation (including metacresol, phenol, glycerol, disodium phosphate dihydrate, sodium chloride, zinc chloride, or hydrochloric acid/sodium hydroxide used for pH adjustment)
- Intravenous administration: NovoMix must never be given intravenously. The protamine-crystallised component is designed only for subcutaneous absorption — intravenous use would cause severe, unpredictable hypoglycaemia and potentially fatal overdose
- Intramuscular administration: Intramuscular injection is not recommended because absorption rates differ unpredictably from subcutaneous injection
- Use in continuous subcutaneous insulin infusion (CSII) pumps: Biphasic formulations including NovoMix must never be used in insulin pumps; only rapid-acting monocomponent insulin aspart (NovoRapid) is suitable for pump therapy
Warnings and Precautions
Several important precautions should be observed when using NovoMix:
- Blood glucose monitoring: Regular self-monitoring of blood glucose (SMBG) is essential. Target ranges should be individualised through consultation with your healthcare provider. Inadequate monitoring increases the risks of both hypoglycaemia and hyperglycaemia
- Injection technique and site rotation: Rotate injection sites within the same body region (abdomen, thigh, upper arm, or buttock) at each injection to reduce the risk of lipodystrophy — changes in the fat tissue under the skin. The absorption rate may vary between body regions, with the abdomen typically providing the most consistent absorption
- Dose adjustments for illness and lifestyle: Insulin requirements may change substantially during illness (especially febrile infections), emotional stress, changes in physical activity levels, or alterations in diet. Your doctor may need to adjust your dose during these periods
- Hypoglycaemia unawareness: Some patients may lose the ability to recognise early warning symptoms of low blood glucose. This is more likely in those with long-standing diabetes, frequent hypoglycaemic episodes, autonomic neuropathy, or who take beta-blockers. Strategies to restore hypoglycaemia awareness include relaxing glycaemic targets temporarily and avoiding further lows
- Renal impairment: Insulin requirements may be reduced in patients with kidney disease because insulin is partly eliminated by the kidneys. Closer monitoring and more frequent dose reductions may be necessary
- Hepatic impairment: Liver disease can alter insulin requirements unpredictably. Hepatic impairment may reduce the liver's capacity for gluconeogenesis (predisposing to hypoglycaemia) but also reduces insulin clearance
- Hypokalaemia: Insulin causes a shift of potassium from the extracellular to the intracellular compartment, potentially causing hypokalaemia. This is particularly important in patients taking potassium-lowering drugs (e.g., loop diuretics), or in those with conditions predisposing to low potassium
- Combination with thiazolidinediones: Concomitant use with pioglitazone (or other thiazolidinediones) may increase the risk of congestive heart failure, especially in patients with pre-existing cardiovascular risk factors
- Travel across time zones: Patients should seek advice from their healthcare team before long-distance travel, as dosing schedules may need adjustment
NovoMix FlexPens, Penfill cartridges, and needles must never be shared between patients, even if the needle is changed between uses. Sharing creates a serious risk of transmitting blood-borne infections including hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV), because microscopic amounts of blood can be drawn back into the insulin reservoir.
Pregnancy and Breastfeeding
Tight glycaemic control during pregnancy is critically important for both maternal and fetal health. Uncontrolled hyperglycaemia during pregnancy increases the risk of pre-eclampsia, preterm birth, macrosomia (large baby), shoulder dystocia, neonatal hypoglycaemia, respiratory distress syndrome, and perinatal death. Insulin aspart has been studied in pregnant women and is considered compatible with pregnancy when clinically indicated.
Insulin requirements typically change in predictable patterns during pregnancy: they often decrease during the first trimester (particularly weeks 8–16), rise progressively during the second and third trimesters due to placental anti-insulin hormones, and fall rapidly after delivery, often returning to pre-pregnancy levels within 24–72 hours. Women with diabetes who are pregnant or planning pregnancy should have preconception counselling and close follow-up by a multidisciplinary team including an obstetrician, endocrinologist, and diabetes nurse specialist.
Insulin aspart is compatible with breastfeeding. Insulin is a large protein molecule and is broken down in the gastrointestinal tract of the infant, so it is not absorbed intact and poses no pharmacological risk to the nursing baby. Nursing mothers may require reduced insulin doses and adjustments to their meal plan to accommodate the metabolic demands of lactation.
Fertility: No adverse effects on fertility have been reported with insulin aspart in animal studies or clinical use.
How Does NovoMix Interact with Other Drugs?
Many medications can affect blood glucose levels and alter the response to NovoMix. Drugs that enhance insulin sensitivity or independently lower glucose can increase the risk of hypoglycaemia; others reduce insulin action and may cause hyperglycaemia. Always tell your prescriber about every medication, supplement, and herbal product you take.
Drug interactions with insulin are clinically significant because they can cause dangerous hypoglycaemia or worsening hyperglycaemia. Because many common medications (e.g., corticosteroids, antihypertensives, antipsychotics) affect glucose metabolism, it is essential to inform your healthcare provider about all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you are taking. The tables below summarise the most clinically important interactions.
Major Interactions (Increased Hypoglycaemia Risk)
The following medications significantly lower blood glucose or enhance insulin effect, potentially requiring NovoMix dose reduction or increased glucose monitoring:
| Drug / Drug Class | Mechanism | Clinical Action |
|---|---|---|
| Sulfonylureas (glimepiride, glipizide, glyburide/glibenclamide) | Stimulate endogenous insulin secretion from pancreatic beta cells; additive glucose-lowering with exogenous insulin | Monitor blood glucose closely; dose reduction of one or both agents is often required when starting combination |
| GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, exenatide) | Enhance glucose-dependent insulin secretion and slow gastric emptying | Reduce insulin dose by 20–30% when initiating GLP-1 therapy in well-controlled patients |
| DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) | Prolong endogenous incretin action; modest additive glucose-lowering | Monitor glucose when starting; modest insulin dose reduction may be required |
| ACE inhibitors (enalapril, lisinopril, ramipril) and ARBs (losartan, valsartan) | May enhance insulin sensitivity, particularly in patients with hypertension and diabetes | Monitor blood glucose when starting or stopping; dose adjustment may be needed |
| MAO inhibitors (phenelzine, moclobemide) | May enhance insulin-mediated glucose uptake and reduce hepatic gluconeogenesis | Enhanced blood glucose monitoring; dose reduction may be required |
| High-dose salicylates (aspirin >3 g/day) | Increase peripheral glucose utilisation and inhibit hepatic glucose output | Monitor blood glucose when initiating or discontinuing high-dose salicylate therapy |
| Fibrates (fenofibrate, gemfibrozil) | May improve insulin sensitivity through effects on lipid metabolism | Monitor blood glucose; insulin dose adjustment may be needed |
| Anabolic steroids and testosterone | Enhance insulin sensitivity and glucose uptake | Monitor glucose when starting; dose reduction may be needed |
| Fluoxetine (and other SSRIs) | May improve insulin sensitivity and decrease appetite | Monitor blood glucose when starting or stopping SSRI therapy |
Drugs That Reduce Insulin Effect (Hyperglycaemia Risk)
The following medications may raise blood glucose or reduce insulin action, potentially requiring a NovoMix dose increase:
| Drug / Drug Class | Mechanism | Clinical Action |
|---|---|---|
| Systemic corticosteroids (prednisolone, dexamethasone, hydrocortisone) | Increase hepatic gluconeogenesis and induce insulin resistance; strong hyperglycaemic effect | Significant insulin dose increases usually required (often 20–100%); monitor glucose frequently; anticipate dose reductions when tapering steroid |
| Thiazide and thiazide-like diuretics (hydrochlorothiazide, indapamide) | Reduce insulin secretion and increase peripheral insulin resistance, partly via hypokalaemia | Monitor blood glucose; adjust insulin dose as needed, especially at higher diuretic doses |
| Combined oral contraceptives | Oestrogens and progestins may reduce insulin sensitivity | Monitor blood glucose when starting or stopping; dose adjustment may be needed |
| Thyroid hormones (levothyroxine) | Increase hepatic glucose output and intestinal glucose absorption | Monitor glucose during thyroid dose changes; especially relevant in newly diagnosed hypothyroidism |
| Sympathomimetics (salbutamol, terbutaline, adrenaline) | Stimulate glycogenolysis and gluconeogenesis via beta-2 adrenergic pathways | Monitor blood glucose; systemic use may require insulin dose increases (inhaled use: minimal effect) |
| Atypical antipsychotics (olanzapine, clozapine, quetiapine, risperidone) | Cause weight gain, insulin resistance, and impaired glucose metabolism | Monitor blood glucose and HbA1c regularly; insulin dose may need to be increased |
| Danazol | Androgenic properties increase insulin resistance | Monitor blood glucose; dose adjustment may be needed |
| Growth hormone (somatropin) | Decreases insulin sensitivity and increases hepatic glucose production | Monitor glucose closely during growth hormone therapy |
| Protease inhibitors (ritonavir, lopinavir) | Associated with insulin resistance, dyslipidaemia, and new-onset diabetes in HIV patients | Regular glucose monitoring; insulin dose may need to be increased |
Beta-blockers (e.g., propranolol, atenolol, metoprolol, bisoprolol) deserve particular attention in patients on insulin. Non-selective beta-blockers can mask the adrenergic warning symptoms of hypoglycaemia (tremor, palpitations, tachycardia), while sweating tends to be preserved. They may also delay glucose recovery by inhibiting glycogenolysis. Cardioselective beta-1 blockers (bisoprolol, metoprolol) have less effect on warning symptoms and are generally preferred when a beta-blocker is clinically needed in a patient with diabetes. Patients should be counselled about recognising alternative hypoglycaemia symptoms such as sweating, hunger, difficulty concentrating, and confusion.
Octreotide, lanreotide, and pasireotide: Somatostatin analogues may either increase or decrease insulin requirements because they suppress the secretion of both insulin and glucagon. Close monitoring is required when starting, stopping, or changing the dose.
Alcohol: Alcohol consumption can both increase and decrease blood glucose unpredictably. Moderate alcohol intake may enhance the hypoglycaemic effect of insulin and impair the liver's glucose counter-regulation, increasing the risk of delayed hypoglycaemia — particularly on an empty stomach or overnight. Sweet alcoholic drinks (cocktails, liqueurs) can initially raise glucose. Patients should monitor glucose more frequently when consuming alcohol and never drink on an empty stomach.
What Is the Correct Dosage of NovoMix?
NovoMix dosing is highly individualised based on blood glucose levels, body weight, metabolic needs, dietary habits, and physical activity. There is no single "correct" dose — your healthcare provider will determine and refine your dose through regular monitoring and titration.
Insulin dosing must be individualised for each patient. The total daily insulin requirement for most adults with diabetes ranges from 0.5 to 1.0 U/kg/day, although this can vary widely depending on the type and duration of diabetes, the degree of insulin resistance, physical activity level, and dietary patterns. The prescribing physician will determine the starting dose and adjust it based on self-monitored blood glucose (SMBG) results and HbA1c values. NovoMix 50 is most commonly administered twice daily — before breakfast and before the evening meal — but some patients benefit from a three-times-daily regimen.
Adults
Type 2 Diabetes — Adults
Starting dose: When initiating insulin in a patient not previously treated with insulin, a typical starting dose is 0.2–0.4 U/kg/day, divided between the two main meals. For patients transitioning from oral antihyperglycaemic agents alone, a common starting approach is 6–12 units before breakfast and 6–12 units before the evening meal.
Administration: Inject subcutaneously immediately before a meal. If necessary, NovoMix can be given shortly after the meal has started. Typically twice daily, before breakfast and before the evening meal. Some patients benefit from three-times-daily dosing, particularly those with persistent postprandial hyperglycaemia at lunch.
Dose titration: Adjust the evening dose based on fasting (pre-breakfast) glucose and the morning dose based on pre-evening-meal glucose. A typical titration is by 2–4 units every 3–7 days until target glucose levels are reached. ADA-recommended targets are typically fasting glucose 4.4–7.2 mmol/L (80–130 mg/dL) and postprandial glucose below 10.0 mmol/L (180 mg/dL).
Type 1 Diabetes — Adults
Total daily dose: Typically 0.5–1.0 U/kg/day, with individual variation from approximately 0.3 U/kg in very lean patients to 1.5 U/kg or more in obese or insulin-resistant patients. NovoMix may be used as part of a two- or three-injection regimen, depending on individual needs and meal patterns.
Administration: Usually twice daily before the main meals (breakfast and evening meal) or three times daily (breakfast, lunch, and evening meal). The dose distribution depends on individual meal patterns, glucose responses, and lifestyle.
Note: Most patients with type 1 diabetes achieve better control with a basal-bolus regimen using separate long-acting and rapid-acting insulins. A premixed biphasic insulin such as NovoMix may be considered for patients who prefer fewer injections, have difficulty managing complex regimens, or have stable meal patterns.
Children and Adolescents
Children and Adolescents Aged 10 Years and Older
Total daily dose: Typically 0.5–1.0 U/kg/day in prepubertal children, increasing to approximately 1.0–2.0 U/kg/day during puberty because of growth-hormone-driven insulin resistance. Dosing must be carefully individualised and supervised by a paediatric endocrinologist or paediatric diabetes team.
Administration: Same principle as in adults — inject immediately before a meal. The abdomen and thigh are commonly preferred injection sites in adolescents; the upper arm and buttock are alternatives.
Important: NovoMix is not recommended for use in children under 10 years of age due to insufficient clinical data in this population. For children under 10 who require a rapid-acting insulin analogue, NovoRapid (monocomponent insulin aspart) is typically preferred.
Elderly Patients
Patients Over 65 Years
Dosing considerations: Elderly patients may have age-related reductions in renal clearance, altered insulin sensitivity, irregular eating patterns, and cognitive or visual impairments that complicate self-management. Starting doses should be conservative, and titration should be gradual. Less stringent glycaemic targets (e.g., HbA1c below 7.5–8.0% or 58–64 mmol/mol) are appropriate for frail elderly patients or those with multiple comorbidities, reflecting the increased risks associated with hypoglycaemia.
Monitoring: More frequent blood glucose monitoring is recommended. The risk of hypoglycaemia is higher in elderly patients and its consequences are more serious — falls leading to hip fractures, acute cardiovascular events, and cognitive decline have all been linked to severe hypoglycaemic episodes in older adults.
Special Populations
Renal or Hepatic Impairment
Insulin requirements may be reduced in patients with renal or hepatic impairment because of reduced insulin clearance and/or reduced gluconeogenic capacity. There are no specific dose recommendations — dosing should be individualised based on frequent blood glucose monitoring and clinical judgement. Expect to adjust doses downward as kidney or liver function deteriorates.
Missed Dose
If you miss a dose of NovoMix:
- Check your blood glucose level immediately
- If blood glucose is elevated and it is still before or close to the missed meal, inject the missed dose and eat
- If it is close to your next scheduled dose, skip the missed dose and resume your regular schedule; do not combine doses
- Never inject a double dose to compensate for a missed injection
- If you are unsure about what to do, contact your healthcare provider, pharmacist, or diabetes educator
- Monitor blood glucose more frequently for the next 24 hours until levels stabilise
Overdose
An insulin overdose causes hypoglycaemia, which may range from mild (sweating, tremor, hunger, irritability) to severe (confusion, loss of consciousness, seizures, coma). The severity depends on the magnitude of overdose, the patient's usual dose, food intake, and physical activity. Severe hypoglycaemia from insulin overdose can be fatal without prompt treatment.
Mild to moderate hypoglycaemia (conscious, able to swallow): Treat immediately by consuming 15–20 grams of fast-acting carbohydrate such as glucose tablets, 100–150 ml of fruit juice, 150 ml of regular (non-diet) soda, or 3–4 teaspoons of sugar dissolved in water. Recheck blood glucose after 15 minutes and repeat if needed. Once glucose is >4.0 mmol/L (72 mg/dL), eat a complex carbohydrate snack such as bread, crackers, or a small meal to prevent recurrence.
Severe hypoglycaemia (unconsciousness, seizures, inability to swallow): Do not attempt to give food or drink by mouth — aspiration risk. Administer glucagon (1 mg intramuscularly or subcutaneously for adults, or 0.5 mg for children under 25 kg) if available; alternatively, nasal glucagon 3 mg. Call emergency services immediately. Place the patient in the recovery position. Intravenous glucose (20% or 50% dextrose) will be administered by medical professionals. After recovery, oral carbohydrates should be given to replenish glycogen stores.
What Are the Side Effects of NovoMix?
The most common side effect of NovoMix is hypoglycaemia (low blood glucose). Other recognised effects include injection site reactions, lipodystrophy, transient oedema, visual changes when initiating therapy, and rare allergic reactions. Most side effects are predictable and manageable with correct technique and monitoring.
Like all insulins, NovoMix can cause side effects, although not every patient experiences them. The most clinically significant adverse reaction is hypoglycaemia, which can occur if the insulin dose is too high relative to food intake or if physical activity is unusually intense. The frequency-based classification below follows the MedDRA/EMA convention and is derived from clinical trial data and post-marketing surveillance reported in the EMA Summary of Product Characteristics (SmPC) and FDA prescribing information.
Very Common
- Hypoglycaemia — Low blood glucose causing symptoms such as sweating, tremor, hunger, dizziness, palpitations, tingling in the lips, difficulty concentrating, confusion, visual disturbances, and in severe cases loss of consciousness, seizures, or coma. Severe hypoglycaemia can be fatal without prompt treatment
Common
- Injection site reactions — Redness, swelling, itching, pain, bruising, or inflammation at the injection site. Usually mild and transient; typically resolve within a few days
- Lipodystrophy — Thickening (lipohypertrophy) or thinning (lipoatrophy) of the subcutaneous fat at injection sites. Reduced by consistent site rotation
- Peripheral oedema — Mild swelling of hands, ankles, or feet, particularly when initiating insulin therapy or during rapid improvements in glycaemic control
Uncommon
- Refractive disorders / transient visual disturbances — Blurred vision when starting insulin or after major changes in glycaemic control, caused by osmotic changes in the lens. Usually resolves spontaneously within a few weeks
- Diabetic retinopathy progression — Rapid improvement in glucose control can transiently worsen pre-existing diabetic retinopathy. Long-term, tight glycaemic control reduces retinopathy progression
- Local allergic reactions — More extensive redness, swelling, pruritus, or urticaria at the injection site that may extend beyond the immediate injection area
- Cutaneous amyloidosis — Skin lumps at injection sites that can unpredictably alter insulin absorption. Avoid injecting into affected areas
- Peripheral neuropathy (treatment-induced) — Painful neuropathy can occasionally develop or worsen transiently when glucose control improves rapidly in previously poorly controlled patients
Rare / Very Rare
- Generalised hypersensitivity reactions — Widespread skin rash, urticaria, angioedema, bronchospasm, hypotension, tachycardia, or anaphylaxis. Requires immediate medical attention and discontinuation of the insulin product
- Insulin antibody formation — Rare development of antibodies that may reduce insulin efficacy, requiring dose adjustment or a switch to a different insulin preparation
- Protamine hypersensitivity — Patients with known protamine allergy (e.g., previously exposed through protamine-containing insulins such as NPH, or through protamine sulfate used for heparin reversal) may experience allergic reactions
Seek immediate medical attention for: signs of severe hypoglycaemia (confusion, loss of consciousness, seizures), severe allergic reactions (widespread rash, difficulty breathing, rapid heartbeat, swelling of face or throat, anaphylaxis), or persistent, worsening injection site reactions. Report unexpected or bothersome side effects to your doctor, pharmacist, or the national pharmacovigilance authority in your country (e.g., FDA MedWatch in the US, MHRA Yellow Card in the UK, EudraVigilance in the EU).
How Should You Store NovoMix?
Store unopened NovoMix FlexPens and Penfill cartridges in a refrigerator at 2–8°C. Once in use, keep at room temperature below 30°C for up to 4 weeks (28 days) and do not refrigerate again. Never freeze insulin. Never use NovoMix that looks abnormal after gentle resuspension.
Proper storage of insulin is essential to preserve its biological activity and patient safety. Incorrect storage — particularly exposure to freezing, heat, or direct sunlight — can cause loss of potency, resulting in unexpected hyperglycaemia or unpredictable blood glucose control. Follow these guidelines carefully:
- Unopened (not currently in use): Store in a refrigerator at 2–8°C (36–46°F). Keep in the original carton to protect from light. Do not place directly against the cooling element at the back of the refrigerator, as freezing permanently destroys insulin
- In-use FlexPen or Penfill cartridge: Once opened (first injection taken), the pen or cartridge can be kept at room temperature below 30°C (86°F) for up to 4 weeks (28 days). Do not refrigerate in-use pens, as cold insulin injections are more painful and re-refrigeration can damage the suspension. Discard after 4 weeks even if insulin remains in the device
- Do not freeze: Frozen insulin must be discarded. Once insulin has been frozen, the protein structure is permanently damaged and the product will not work correctly even after thawing
- Protect from heat and light: Do not expose NovoMix to direct sunlight or to temperatures above 30°C. Never leave insulin in a parked car, on a windowsill, or near heat sources such as radiators or ovens
- Expiry date: Do not use after the expiry date printed on the carton and pen label, even if the insulin has been stored correctly
- Before every injection: Gently roll the pen between your palms 10 times, then move it up and down (inverting) 10 times so the glass ball inside mixes the suspension. The liquid should appear uniformly white and cloudy after mixing. Do not use if it remains clear, contains visible clumps, or has white particles sticking to the cartridge wall or bottom
- Needle disposal: Remove the needle after each injection and dispose of it safely in an approved sharps container. Never recap needles — this is a leading cause of needle-stick injuries
- Keep out of reach of children: Store FlexPens and Penfill cartridges in a safe place inaccessible to children
When travelling, keep insulin in a cool insulated bag (not in direct contact with ice packs, which can cause freezing). Never place insulin in checked luggage on aircraft — cargo holds can reach sub-zero temperatures. Always carry a prescription or a letter from your physician when travelling internationally, especially through airport security, and carry more insulin than you expect to need in case of travel delays. Time zone changes may require dose timing adjustments; discuss with your diabetes team before long-distance travel.
What Does NovoMix Contain?
NovoMix 50 contains insulin aspart as the active substance (50% soluble, 50% protamine-crystallised). Excipients include phenol, metacresol, glycerol, zinc chloride, disodium phosphate dihydrate, sodium chloride, protamine sulfate, and water for injection, with hydrochloric acid or sodium hydroxide used to adjust pH.
Each millilitre of NovoMix 50 suspension for injection contains the following:
- Active substance: Insulin aspart 100 U (equivalent to 3.5 mg). Of this, 50% is soluble insulin aspart (rapid-acting component) and 50% is protamine-crystallised insulin aspart (intermediate-acting component)
- Protamine sulfate: Complexed with insulin aspart to slow absorption and create the intermediate-acting fraction
- Metacresol: Preservative (antimicrobial)
- Phenol: Preservative; also stabilises insulin hexamer structure
- Glycerol: Tonicity modifier (ensures the solution is isotonic)
- Zinc chloride: Stabiliser (required for insulin crystal formation)
- Disodium phosphate dihydrate: Buffer to maintain appropriate pH
- Sodium chloride: Tonicity modifier
- Water for injection: Vehicle
- Hydrochloric acid and/or sodium hydroxide: pH adjustment (target pH approximately 7.2–7.4)
Insulin aspart is produced by recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast). The manufacturing process involves fermentation, purification, crystallisation, and extensive quality control in accordance with European Pharmacopoeia and FDA regulatory standards. The final product is sterile, free from endotoxins, and tested for biological potency.
Available presentations: NovoMix 50 is supplied as a 3 ml pre-filled disposable injection pen (NovoMix 50 FlexPen) or a 3 ml cartridge (NovoMix 50 Penfill) for use in compatible reusable Novo Nordisk pen devices such as the NovoPen series. Both presentations contain 100 units of insulin per millilitre (U-100).
Allergy information: Patients with a known allergy to protamine may be at increased risk of hypersensitivity reactions to NovoMix because of the protamine sulfate content. Protamine allergy is more common in patients previously exposed to protamine-containing medications, including NPH insulin, other biphasic insulins, or protamine sulfate used to reverse heparin anticoagulation. Always inform your healthcare provider of any previous insulin or protamine allergies before starting NovoMix.
Frequently Asked Questions About NovoMix
The number in the name indicates the percentage of soluble rapid-acting insulin aspart in the biphasic mixture. NovoMix 30 contains 30% rapid-acting and 70% intermediate-acting insulin aspart — well suited to patients who need more background coverage with modest postprandial correction. NovoMix 50 contains 50% of each, offering a balanced profile. NovoMix 70 contains 70% rapid-acting and 30% intermediate-acting, providing strong postprandial control with less background effect. The choice depends on your blood glucose patterns, meal composition, and lifestyle. Some patients even combine different mixes at different meals (for example Mix 50 at breakfast and Mix 30 at dinner) to match individual needs.
Yes, insulin aspart (including biphasic formulations such as NovoMix) can be used during pregnancy when clinically indicated. Good glycaemic control is essential throughout pregnancy to reduce the risks of pre-eclampsia, macrosomia, birth injuries, and neonatal hypoglycaemia. Insulin requirements typically decrease in the first trimester and rise during the second and third trimesters because of placental anti-insulin hormones. Close, frequent glucose monitoring and regular dose adjustments with your diabetes team are essential. After delivery, insulin requirements usually fall rapidly back to pre-pregnancy levels within 24–72 hours.
The rapid-acting component of NovoMix 50 begins lowering blood glucose within 10 to 20 minutes of subcutaneous injection, which is faster than biphasic human insulin. Peak glucose-lowering activity occurs between 1 and 4 hours after injection. The protamine-crystallised component extends the overall duration of action to approximately 14–24 hours. Because of this rapid onset, NovoMix should be injected immediately before a meal (or, exceptionally, shortly after the meal has started) rather than the 30–60 minutes before meals that older regular insulins require.
No. NovoMix is already a precisely manufactured biphasic insulin formulation containing a fixed ratio of rapid-acting and intermediate-acting insulin aspart. Mixing it with other insulins (such as NovoRapid, Levemir, or any other insulin product) in the same syringe could alter the absorption profile and lead to unpredictable blood glucose control. If your treatment plan requires different insulin types, they must be administered as separate injections, ideally at different injection sites.
If you experience symptoms of hypoglycaemia (sweating, tremor, hunger, dizziness, palpitations, confusion, blurred vision), follow the 15/15 rule: consume 15–20 grams of fast-acting carbohydrate such as 3–4 glucose tablets, 150 ml of fruit juice, or 150 ml of regular (non-diet) soft drink. Wait 15 minutes and recheck your blood glucose. If still low, repeat the carbohydrate intake. Once glucose has normalised (>4.0 mmol/L), eat a small complex-carbohydrate snack with protein (e.g., bread with cheese, crackers with peanut butter) to prevent recurrence. If you experience severe hypoglycaemia with inability to eat, loss of consciousness, or seizures, a caregiver should administer glucagon injection or nasal glucagon immediately and call emergency services.
Before each injection, resuspend the insulin: gently roll the FlexPen between your palms 10 times, then move it up and down (inverting) 10 times until the liquid appears uniformly cloudy white. Attach a new pen needle and remove the outer and inner caps. Perform a safety test by dialling 2 units and pushing the dose button with the needle pointing upward until a drop appears. Dial your prescribed dose. Select an injection site (abdomen, thigh, upper arm, or buttock) and rotate sites within the same region. Pinch a fold of skin if you are lean, and insert the needle at a 90-degree angle (or 45 degrees in very slim patients or children). Press the injection button fully and hold the needle in place for at least 6–10 seconds after the dose counter reaches zero to ensure complete delivery. Remove the needle and dispose of it safely in a sharps container.
No. NovoMix must not be used in continuous subcutaneous insulin infusion (CSII) pumps. The intermediate-acting protamine-crystallised component is specifically designed for slow release after subcutaneous injection and is not suitable for pump delivery — it would clog the infusion set and deliver insulin unpredictably. Patients who need pump therapy should use a monocomponent rapid-acting insulin such as NovoRapid (insulin aspart), Humalog (insulin lispro), or Apidra (insulin glulisine) — your endocrinologist will recommend the most suitable option.
References
- European Medicines Agency (EMA). NovoMix — Summary of Product Characteristics (SmPC). Novo Nordisk A/S. Updated 2024. Available at: EMA EPAR NovoMix.
- U.S. Food and Drug Administration (FDA). Insulin aspart prescribing information. Novo Nordisk Inc. Updated 2024.
- American Diabetes Association (ADA). Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S1–S352.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Insulin preparations including insulin aspart.
- Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589–2625.
- Christiansen JS, Vaz JA, Metelko &Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2003;5(6):446–454.
- Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265.
- British National Formulary (BNF). Insulin aspart (biphasic). National Institute for Health and Care Excellence (NICE). Updated 2025.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th edition, 2021.
- Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology. 2017;13(7):385–399.
- Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism. 2006;8(1):58–66.
Editorial Team
Medical Content
iMedic Medical Editorial Team
Specialists in endocrinology, clinical pharmacology, and internal medicine. All content is based on current international guidelines (ADA, EASD, EMA, FDA, WHO) and peer-reviewed research.
Medical Review
iMedic Medical Review Board
Independent panel of board-certified physicians who review all content according to the GRADE evidence framework and international medical standards.
Evidence Standard: All medical claims in this article are based on Level 1A evidence (systematic reviews and meta-analyses of randomised controlled trials) or official regulatory documents (EMA SmPC, FDA label). No commercial funding was received. This content is independent of pharmaceutical industry influence.